Key facts
- It has raised $180K; the latest was Later Stage VC ($10K) in May 2025.
- Notable investors include Busan United Holdings (Busan), Korea University Holdings, Sazze Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for GraBis
- ·The full record, as it builds
Funding rounds
No funding rounds for GraBis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GraBis
Developer of diagnostic technologies designed to detect disease-specific biomarkers with high precision. The company's platform offers magnetic nanoparticle-based detection and targeted biomarker analysis capabilities, enabling clinicians and diagnostic laboratories to accurately and efficiently identify critical health conditions across multiple fatal disease groups.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 8
- Website
- grabis.co.kr/
- Ownership
- Privately Held (backing)
GraBis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GraBis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GraBis in its N-PORT filings yet. We sweep new filings monthly.